Entresto (Sacubitril/​Valsartan) & Angioedema

Basic Details
Status
Ongoing
Last Updated
Wednesday, April 21, 2021
Original Posting Date
Health Outcome(s)
angioedema
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
Yes
Analytic Code Link(s) (1)
Angioedema following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis
Result(s) (3)
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis Utilization of Sacubitril/Valsartan: A Descriptive Analysis Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure